Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Model N Brings Revenue Management Platform To Hyderabad
Model N is expected to invest 80 to 100 crores in its Indian operations over the next three years by recruiting in the areas of product development, professional
Model N is expected to invest 80 to 100 crores in its Indian operations over the next three years by recruiting in the areas of product development, professional
Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically
Watson Pharmaceuticals said that the launch was a part of a settlement agreement with Novartis Pharmaceuticals, Novartis Pharma, Novartis AG, Novartis International, and Proterra (collectively Novartis). Exelon is
The arrangement, which is effective as of the July 1, 2010, provides for ongoing employment of the staff at the centre and for Aptuit to supply GSK with
Sapacitabine is an oral nucleoside analog prodrug that acts through a dual mechanism. The compound interferes with DNA synthesis by causing single-strand DNA breaks and induces arrest of
Zegerid, a registered trademark of Santarus, is known to contain omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus
Thomas Kindt, chief scientific officer of InNexus, said: “Under the existing collaborative agreement, the NCI is expected to continue to evaluate our proprietary technology as applied to certain
Furiex Pharma has developed Dapoxetine in collaboration with Alza Corporation and its affiliates. The patent include claims directed to dosing Dapoxetine on an as-needed basis, capturing the advantage
Under the terms of the agreement, X-Chem is expected to get an upfront and research payments, success-based discovery milestones, and technology access fees from Roche. Roche is expected
The FDA has indicated that the single 50-patient open-label Phase 3 study of Corlux, which is being conducted at 20 medical facilities throughout the US, may provide a